Financial Performance - The company's operating revenue for Q1 2024 was ¥91,062,636.90, representing a year-on-year increase of 24.46%[5] - The net profit attributable to shareholders was -¥1,672,840.41, with a significant increase in net loss compared to the previous year[5] - Total revenue for Q1 2024 reached ¥91,062,636.90, a 24.4% increase from ¥73,168,207.49 in Q1 2023[18] - Net profit for Q1 2024 was a loss of ¥3,684,677.11, an improvement from a loss of ¥18,642,741.10 in Q1 2023[19] - Total comprehensive income for Q1 2024 was a loss of ¥5,003,621.26, compared to a loss of ¥19,139,644.82 in Q1 2023[19] Research and Development - Research and development expenses totaled ¥40,560,514.19, accounting for 44.54% of operating revenue, an increase of 2.99 percentage points year-on-year[6] - The company added eLum to its consolidated scope, contributing to increased R&D costs across various categories[9] - Research and development expenses rose to ¥36,009,056.49 in Q1 2024, up 35.4% from ¥26,583,394.30 in Q1 2023[18] - Research and development expenses for Q1 2024 were CNY 7,076,116.53, down from CNY 8,715,645.88 in Q1 2023, reflecting a decrease of approximately 18.8%[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,275,418,626.59, reflecting a 7.56% increase from the end of the previous year[6] - The company's total current assets rose to CNY 307,807,885.11, compared to CNY 286,299,842.73 at the end of 2023, marking an increase of about 7.4%[24] - The total liabilities of the company were RMB 395,630,423.74, which is an increase from RMB 324,171,588.85, representing a growth of around 22.1%[15] - The company's long-term liabilities increased to RMB 235,587,162.35 from RMB 172,899,093.28, representing a growth of approximately 36.3%[15] - The total liabilities increased to CNY 301,940,030.53 as of March 31, 2024, compared to CNY 240,066,782.01 at the end of 2023, showing an increase of about 25.7%[25] Cash Flow - Operating cash flow for Q1 2024 showed a net outflow of ¥16,218,315.41, compared to a net outflow of ¥19,993,202.99 in Q1 2023[21] - The company generated ¥87,527,487.94 in cash from financing activities in Q1 2024, compared to ¥17,000,000.00 in Q1 2023[22] - The net cash flow from operating activities was -CNY 9,478,350.67, an improvement from -CNY 12,337,600.64 in the same period last year[30] - The net cash flow from financing activities was CNY 72,818,883.96, up from CNY 19,298,666.67 in Q1 2023, indicating a strong increase in financing[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,173, with the largest shareholder holding 17.53% of the shares[10] - The company's equity attributable to shareholders was RMB 817,378,486.78, slightly down from RMB 819,957,004.39, showing a decrease of about 0.3%[16] - The total owner's equity reached CNY 1,103,981,155.96 as of March 31, 2024, slightly up from CNY 1,099,238,457.97 at the end of 2023, reflecting a growth of about 0.4%[25] Earnings Per Share - The basic and diluted earnings per share were both -¥0.004, indicating a 90% increase in loss per share compared to the previous year[9] - Basic and diluted earnings per share for Q1 2024 were both -¥0.004, an improvement from -¥0.04 in Q1 2023[19]

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥213,692,262.55, representing a 32.49% increase compared to ¥161,285,944.35 in the same period last year[20]. - The net profit attributable to shareholders was ¥3,490,568.65, a significant recovery from a loss of ¥29,611,147.98 in the previous year[20]. - The total assets increased by 9.93% to ¥1,303,564,738.46 from ¥1,185,821,379.98 at the end of the previous year[20]. - The net assets attributable to shareholders rose by 5.79% to ¥867,403,664.40 from ¥819,957,004.39 at the end of the previous year[20]. - The basic and diluted earnings per share were both ¥0.01, reflecting a growth of 114.29% year-on-year[25]. - The weighted average return on equity was 0.42%, up by 3.96 percentage points from the previous year[25]. - The net cash flow from operating activities was ¥13,002,580.28, down 16.72% from ¥15,612,531.32 in the same period last year[20]. - The net profit attributable to shareholders reached CNY 7.662 million, marking a significant increase of 125.88% compared to the previous year[94]. - The company's operating revenue growth was primarily driven by a 70.77% increase in coronary intervention business revenue, attributed to the implementation of the national centralized procurement policy for coronary stents[97]. Research and Development - Research and development expenses accounted for 43.16% of operating revenue, a decrease of 6.69 percentage points year-on-year[25]. - The company achieved a total R&D investment of CNY 92.23 million, accounting for 43.16% of its revenue[47]. - The company has developed a total of 22 products across 6 categories in the coronary and neurovascular fields, enhancing its product diversification and risk resistance[67]. - The company has established a comprehensive R&D platform for new product development, focusing on innovative drug delivery systems[42]. - The company has received multiple patent authorizations for its retractable, self-locking mitral valve replacement technology, aimed at providing a minimally invasive treatment for severe mitral regurgitation[51]. - The company has a structured emergency response plan for potential environmental incidents, ensuring efficient and orderly management[133]. - The company is advancing research on supercritical carbon dioxide (sc-CO2) technology, with a budget of 6.46 million RMB aimed at evaluating its feasibility in interventional products by 2024[62]. Market and Product Development - The coronary intervention business revenue grew by 70.77%, driven by increased sales of stent and balloon products[23]. - The company is focusing on expanding its product offerings and enhancing its research capabilities in the biomedical engineering sector[31]. - The company has successfully launched multiple leading coronary and neurointerventional products, with cumulative usage reaching nearly 2 million across over 3,000 hospitals in China and benefiting hundreds of thousands of patients in Southeast Asia, Europe, and South America[35]. - The company is expanding its product line with the introduction of the TORR negative pressure suction pump, aimed at enhancing surgical suction capabilities in hospitals[40]. - The company is actively developing new products, including the OLLIEE™ and HONKYTONK™ balloon catheters, aimed at improving myocardial perfusion in patients with coronary artery disease[38]. - The company has made significant progress in developing multiple new products in the neurointerventional field, with all projects proceeding as planned[49]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[4]. - Despite significant growth in revenue and net profit, the company still faces risks of continuous losses in 2024 due to competitive pressures and ongoing centralized procurement initiatives[89]. - The company faces risks related to new product development failures or registration delays due to high technical barriers and regulatory challenges in the medical device industry[79]. - There is a risk of talent loss if the company cannot provide competitive compensation and a conducive work environment[80]. - The company is exposed to risks from centralized procurement policies, which may affect sales volume and pricing strategies[83]. Corporate Governance and Compliance - The report is unaudited, and the board of directors has confirmed the accuracy and completeness of the financial report[5]. - The company has not proposed any profit distribution plan or capital reserve transfer to increase share capital for this reporting period[7]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[166]. - The company has maintained a good credit status with no records of violations in the past three years[168]. - The company has not reported any significant litigation or arbitration matters during the reporting period[167]. Environmental and Social Responsibility - The company invested RMB 28.17 million in environmental protection during the reporting period[128]. - The company has established a comprehensive environmental protection mechanism and all pollution control facilities are operating effectively[130]. - The company has no administrative penalties related to environmental issues during the reporting period[135]. - The company has a structured emergency response plan for potential environmental incidents, ensuring efficient and orderly management[133].

赛诺医疗科学技术股份有限公司2025 年第一季度报告 证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真实、 准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期 增减变动幅度(%) | | --- | --- | --- | --- | | 营业收入 | 100,849,103.23 | 91,062,636.90 | 10.75 | | 归属于上市公司股东的净利润 | 2,969,330.70 | -1,672,840.41 | 不适用 | | ...

赛诺医疗科学技术股份有限公司 2024 年度独立董事述职报告（马元驹） 根据中国证监会《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立 董事管理办法》《上海证券交易所科创板股票上市规则》《赛诺医疗科学技术股份有限公司 章程》《赛诺医疗科学技术股份有限公司独立董事工作规则》的有关规定，作为赛诺医疗 科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）的独立董事，本人马元驹在 2024年度工作中能够认真、勤勉、忠实、独立地履行独立董事的各项职责，审慎行使公司 及股东赋予的权利，积极发挥独立董事的监督作用，认真审议各项议案，发挥专业特长， 为公司经营发展提出合理化建议，对公司董事会审议的相关重大事项发表独立客观的意见， 为董事会的科学决策提供支持，促进公司规范、可持续发展，切实维护了公司和股东尤其 是中小股东的合法权益。现将2024年度履行职责情况报告如下： 一、独立董事基本情况 公司董事会由 9 名董事组成，其中独立董事 3 名，占董事会人数的三分之一，符合相 关法律法规及公司制度的规定。 （一）个人工作履历、专业背景以及兼职情况 马元驹，男，汉族，1957年3月生，上海财经大学经济学硕士、中国人 ...

赛诺医疗科学技术股份有限公司 根据中国证监会《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立 董事管理办法》《上海证券交易所科创板股票上市规则》《赛诺医疗科学技术股份有限公司 章程》《赛诺医疗科学技术股份有限公司独立董事工作规则》的有关规定，作为赛诺医疗 科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）的独立董事，本人高岩在 2024年度工作中能够认真、勤勉、忠实、独立地履行独立董事的各项职责，审慎行使公司 及股东赋予的权利，积极发挥独立董事的监督作用，认真审议各项议案，发挥专业特长， 为公司经营发展提出合理化建议，对公司董事会审议的相关重大事项发表独立客观的意见， 为董事会的科学决策提供支持，促进公司规范、可持续发展，切实维护了公司和股东尤其 是中小股东的合法权益。现将2024年度履行职责情况报告如下： 高岩，男，1966年1月出生，中国国籍，无境外永久居留权。北京大学学士（计算数学专 业）、美国密执安州立大学硕士、美国西北大学金融博士，注册金融师。1988至1990年，任北 京物资学院教师；2001年至2003年任美国纽约城市大学访问教授；2003年至2004年任美国加 州州立大学洛杉 ...

赛诺医疗科学技术股份有限公司 （一）个人工作履历、专业背景以及兼职情况 李蕊, 女，1978 年出生，中国国籍，无境外永久居留权。中国人民大学经济法学学士、 中国政法大学民商法学硕士、中国人民大学经济法学博士，中国政法大学经济法学博士后、 美国明尼苏达大学访问学者。2015 年至 2017 年，任职于北京农学院法学系。2017 年起任中 国政法大学民商经济法学院教授，博士生导师，中国政法大学地方财政金融与农村法治研究 中心主任。兼任中国法学会经济法学研究会常务理事、中国法学会财税法学研究会常务理事、 中国农业农村法研究会常务理事、中国法学会银行法学研究会理事等。2020 年 12 月至今担 任赛诺医疗独立董事。 （二）独立董事担任董事会专门委员会的情况 2020年12月至今，本人在公司董事会薪酬与考核委员会担任主任委员，在董事会提名 委员会担任委员。 2024 年度独立董事述职报告（李蕊） 根据中国证监会《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立 董事管理办法》《上海证券交易所科创板股票上市规则》《赛诺医疗科学技术股份有限公司 章程》《赛诺医疗科学技术股份有限公司独立董事工作规则》的有关规 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sainuo Medical, which has a significantly high PE ratio compared to its industry peers [1][2] - As of April 21, Sainuo Medical's closing price was 9.41 yuan, with a PE ratio of 2557.77, marking a new low in 12 days, and a total market capitalization of 3.891 billion yuan [1] - The average PE ratio for the medical device industry is 47.69, with a median of 29.88, positioning Sainuo Medical at the 121st rank within the industry [1][2] Group 2 - Sainuo Medical specializes in the research, development, production, and sales of high-end interventional medical devices, with its main products including coronary stent systems and balloon dilation catheters [1] - The company's primary revenue source is the coronary drug-eluting stent system, and it has been recognized as a "Key Laboratory of Tianjin" and "Tianjin Enterprise Technology Center" [1] - For the third quarter of 2024, Sainuo Medical reported an operating income of 318 million yuan, a year-on-year increase of 30.20%, while the net profit was -6.74 million yuan, reflecting a year-on-year decline of 83.84%, with a gross profit margin of 61.29% [1]

Core Viewpoint - Sino Medical Technology Co., Ltd. will hold an investor briefing on April 28, 2025, to discuss its 2024 annual report and Q1 2025 report, allowing investors to engage in Q&A sessions regarding the company's performance and financial status [2][4]. Group 1: Meeting Details - The investor briefing will take place on April 28, 2025, from 16:00 to 17:00 [3][4]. - The meeting will be conducted via the Shanghai Stock Exchange's online interactive platform [2][4]. - Participants will include the Chairman and General Manager, Mr. Sun Jianhua, the Secretary of the Board, Mr. Huang Kai, and the Chief Financial Officer, Ms. Shen Lihua [4][5]. Group 2: Investor Participation - Investors can participate in the briefing by logging into the Shanghai Stock Exchange's online platform on the scheduled date [5]. - A pre-collection of questions will be available from April 21 to April 25, 2025, allowing investors to submit inquiries via the website or email [2][5]. - After the briefing, the main content and outcomes will be accessible on the Shanghai Stock Exchange's platform [5].

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-010 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）将于 2025 年 4 月 26 日发布《赛诺医疗科学技术股份有限公司 2024 年年度报告》及《赛诺医疗科学技术股份有 限公司 2025 年第一季度报告》，为便于广大投资者更全面深入地了解公司 2024 年度及 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 04 月 28 日下午 16:00-17:00 举行赛诺 医疗 2024 年度暨 2025 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度及 2025 年第一季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者 普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 04 月 28 日 下午 16:00-17:00 赛诺医疗科学技术股份有限公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)121赛诺医疗2465.352465.354.3737.50亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97 亿11中红医疗-48.32-32.870.7743.02亿 来源：金融界 4月16日，赛诺医疗今日收盘9.07元，下跌3.41%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到2465.35倍，总市值37.50亿 ...